lung cancer

소개글

lung cancer에 대한 보고서 자료입니다.

목차

LUNG CANCER

PATHOLOGY

ETIOLOGY

CLINICAL MANIFESTATIONS

EARLY DIAGNOSIS

ESTABLISHING A TISSUE DIAGNOSIS OF LUNG CANCER

STAGING PATIENTS WITH LUNG CANCER

TUMOR (T) STATUS DESCIPTOR

LYMPH NODE (N) INVOLVEMENT DESCRIPTOR

DISTANT METASTASIS (M) DESCRIPTOR

PHYSIOLOGIC STAGING

TREATMENT

본문내용

ntial RT for "nonoperable" patients
Stage IIIA with selected types of stage T3 tumors:
Tumors with chest wall invasion (T3): en bloc resection of tumor with involved chest wall and consideration of postoperative RT
Superior sulcus (Pancoast's) (T3) tumors: preoperative RT (30-45 Gy) followed by en bloc resection of involved lung and chest wall with consideration of postoperative RT or intraoperative brachytherapy
Proximal airway involvement (<2 cm from carina) without mediastinal nodes: sleeve resection if possible preserving distal normal lung or pneumonectomy
Stages IIIA "advanced, bulky, clinically evident N2 disease" (discovered preoperatively) and IIIB disease that can be included in a tolerable RT port:
Curative potential RT +CRx if performance status and general medical condition are reasonable; otherwise, RT alone
Consider neoadjuvant CRx and surgical resection for IIIA disease with advanced N2 involvement
Stage IIIB disease with carinal invasion (T4) but without N2 involvement:
Consider pneumonectomy with tracheal sleeve resection with direct reanastomosis to contralateral mainstem bronchus
Stage IV and more advanced IIIB disease:
RT to symptomatic local sites
CRx for ambulatory patients
Chest tube drainage of large malignant pleural effusions
Consider resection of primary tumor and metastasis for isolated brain or adrenal metastases
2)Small cell lung cancer
-Limited stage (good performance status): combination CRx + chest RT
-Extensive stage (good performance status): combination CRx
-Complete tumor responders (all stages): prophylactic cranial RT
-Poor-performance-status patients (all stages):
Modified-dose combination CRx
every 3 weeks on an outpatient basis for 4 to 6 cycle
regimen is etopside, cisplatin, and paclitaxel
Palliative RT
3)All patients
-RT for brain metastases, spinal cord compression, weight-bearing lytic bony lesions, symptomatic local lesions (nerve paralyses, obstructed airway, hemoptysis in non-small cell lung cancer and in small cell cancer not responding to CRx)
-Appropriate diagnosis and treatment of other medical problems and supportive care during CRx
-Encouragement to stop smoking
-Entrance into clinical trial, if eligible

키워드

lung cancer,   lung,   cancer